INCANNEX HEALTHCARE INC.

Highlights Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

Market Closed - Nasdaq Other stock markets 01:28:34 31/05/2024 am IST			5-day change	1st Jan Change
3 ^USD	+2.04%		+11.11%	-35.34%

30/05	Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	CI
15/05	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	30/05	CI
Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05	CI
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	07/05	CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28/02	CI
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	17/02	MT
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	16/02	CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02	CI
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	25/01	CI
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	18/01	CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	17/01	MT
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	17/01	CI
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia	22/12	CI
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	06/12	CI
Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Incannex Healthcare Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	27/23/27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer